medigraphic.com
Colegio de Medicina Interna de México.

2022, Number 3

<< Back Next >>

Med Int Mex 2022; 38 (3)

Application of the IMPROVE bleeding scale in patients at risk of venous thromboembolic disease

Lambis-Loaiza LA

Language: Spanish
References: 49
Page: 586-594
PDF size: 193.35 Kb.


ABSTRACT

Venous thromboembolic disease is a disease consisting of two spectra, deep vein thrombosis and pulmonary embolism, which despite being a disease of high morbidity and mortality, is preventable. In Colombia, this disease has an incidence of 7% in hospitalized medical and surgical patients and carries a mortality risk of 14.8%. As a tool to measure the risk of bleeding, the IMPROVE scale was developed and this, according to the American College of Chest Physicians, should be taken as a basis; the IMPROVE scale consists of 13 variables and the risk of bleeding increases if the patient has a score ≥ 7. The external validation performed on the IMPROVE scale in 2014 shows that it represents a great advance in terms of avoiding unnecessary damage to the hospitalized medical patients when using excessive prophylaxis and also represents a great help in terms of assessing the population at risk for venous thromboembolic disease.


REFERENCES

  1. Arias J, Rodríguez R, Naranjo F. Uso de tromboprofilaxisen pacientes con patología médica. Rev Colomb Cardiol 2016; 23 (5): 375-382.

  2. Martínez-Montalvo CM, Mondragón-Cardona A, Maluche-Osorio A, Tovar-Medina JP, Salamanca-Muñoz DF, Trujillo-Silva GC, et al. Experiencia en el uso de tromboprofilaxisfarmacológica en un hospital colombiano de tercer nivel.Acta Med Peru 2018; 35 (2): 108-15.

  3. Vázquez F, Watman R, Vilaseca A, Rodriguez V, CrucianiA, Korin J. Guía de recomendaciones para la profilaxis dela enfermedad tromboembólica venosa en adultos en laargentina. Medicina 2013; 73 (2): 1-26.

  4. Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, KakkarAK, Deslandes B, Et al; ENDORSE Investigators. Venousthromboembolism risk and prophylaxis in the acutehospital care setting (ENDORSE study): a multinationalcross-sectional study. Lancet 2008; 371 (9610): 387-94.DOI: 10.1016/S0140-6736(08)60202-0.

  5. Gómez I, Súarez C, Gómez JF, Betegón L, de Salas M, RubioC. Impacto presupuestario para el sistema nacionalde salud de la prevención del tromboembolismo venosocon apixabán en pacientes sometidos a artroplastia totalde rodilla o cadera. Rev Esp Salud Pública 2012; 86 (6):

  6. 601-612.6. Romero JJ, Rodríguez RM, Naranjo F. Uso de tromboprofilaxisen pacientes con patología médica. Rev ColombCardiol 2016; 23 (5): 375-382.

  7. White RH. The epidemiology of venous thromboembolism.Circulation 2003; 107 (23 Suppl 1): 14-8. DOI:10.1161/01.CIR.0000078468.11849.66.

  8. Rosenberg DJ, Press A, Fishbein J, Lesser M, McCullaghL, McGinn T, et al. External validation of the IMPROVEBleeding Risk Assessment Model in medical patients.Thromb Haemost 2016; 116 (3): 530-6. DOI: 10.1160/TH16-01-0003.

  9. Decousus H, Tapson VF, Bergmann JF, Chong BH, FroehlichJB, Kakkar AK, et al. IMPROVE investigators.Factors at admissionassociated with bleeding risk in medical patients:findings from the IMPROVE investigators. Chest 2011; 139(1): 69-79. DOI: 10.1378/chest.09-3081.

  10. Ordoñez J, Palacios A. Análisis costo-efectividad de Apixabanversus Enoxaparina en pacientes sometidos a reemplazototal de cadera o rodilla en Colombia. Rev ColombOrtop Traumatol 2016; 30 (4): 133-140.

  11. Johnson SA, Eleazer GP, Rondina MT. Pathogenesis, diagnosis,and treatment of venous thromboembolism inolder adults. J Am Geriatr Soc 2016; 64 (9): 1869-78. DOI:10.1111/jgs.14279.

  12. Prandoni P, Samama MM. Risk stratification and venousthromboprophylaxis in hospitalized medical and cancerpatients. Br J Haematol 2008; 141 (5): 587-97. DOI:10.1111/j.1365-2141.2008.07089.x.

  13. Gerotziafas GT, Papageorgiou L, Salta S, NikolopoulouK, Elalamy I. Updated clinical models for VTE predictionin hospitalized medical patients. Thromb Res 2018; 164(Suppl 1): S62-S69. DOI: 10.1016/j.thromres.2018.02.004.

  14. Spyropoulos AC, Raskob GE. New paradigms in venousthromboprophylaxis of medically ill patients. ThrombHaemost 2017; 117 (9): 1662-1670. DOI:10.1160/TH17-03-0168.

  15. Thériault T, Touchette M, Goupil V, Echenberg D, LanthierL. Thromboprophylaxis adherence to the ninth edition ofAmerican college of chest physicians antithrombotic guidelinesin a tertiary care centre: a cross-sectional study. J EvalClin Pract 2016; 22 (6): 952-957. DOI: 10.1111/jep.12569.

  16. Tapson VF, Decousus H, Pini M, Chong BH, Froehlich JB,Monreal M, Et al. IMPROVE Investigators. Venous thromboembolismprophylaxis in acutely ill hospitalized medicalpatients: findings from the International Medical PreventionRegistry on Venous Thromboembolism. Chest 2007;132 (3): 936-45. DOI: 10.1378/chest.06-2993.

  17. Páramo J, Feliu J, Iglesias R, Ruiz de Gamoa E, Lecumberri R.Profilaxis del tromboembolismo venoso: recomendaciones enpacientes médicos y sistema de alarma electrónico en pacienteshospitalizados. Rev Med Uni Navarra 2006; 50 (1): 17-23.

  18. Schönfeld D, Ortiz C, Vanoni S, López A, Precerutti J, PenizzottoM, Et al. Profilaxis de enfermedad tromboembólicavenosa en pacientes adultos sometidos a cirugía, Estudiomilticéntrico en instituciones públicas y privadas de Argentina.Rev Am Med Resp 2012; 4: 140-147.

  19. Spyropoulos AC, Anderson FA Jr, FitzGerald G, Decousus H,Pini M, Chong BH, et al; IMPROVE Investigators. Predictiveand associative models to identify hospitalized medicalpatients at risk for VTE. Chest 2011; 140 (3): 706-714. DOI:10.1378/chest.10-1944.

  20. Spyropoulos AC, Ageno W, Albers GW, Elliott CG, HalperinJL, Hiatt WR, Et al; MARINER Investigators. Rivaroxabanfor Thromboprophylaxis after Hospitalization for MedicalIllness. N Engl J Med 2018; 379 (12): 1118-1127.DOI:10.1056/NEJMoa1805090.

  21. Cabrera A, Hernández EJ, Guzmán G, Laguna G, Pliego C,Zendejas JL, Et al. Tromboprofilaxis en pacientes médicosy quirúrgicos: resultados de un estudio multicéntrico realizadoen hospitales de la Ciudad de México. Med Int Méx2017; 33 (6): 746-753.

  22. Silveira G, López I, Carlomagno A, De Ándres F, Ventura V,Baccelli A, Et al. Evaluación de la prescripción de tromboprofilaxisfarmacológica y valoración del impacto quegeneran distintas estrategias para mejorar su indicación.Rev Urug Med Interna 2017; 2 (1): 21-24.

  23. Guyatt GH, Akl EA, Crowther M, Gutterman DD, SchuünemannHJ; American College of Chest Physicians AntithromboticTherapy and Prevention of Thrombosis Panel. Executivesummary: Antithrombotic Therapy and Prevention ofThrombosis, 9th ed: American College of Chest PhysiciansEvidence-Based Clinical Practice Guidelines. Chest 2012;141 (2 Suppl) :7S-47S. DOI: 10.1378/chest.1412S3.

  24. Hostler DC, Marx ES, Moores LK, Petteys SK, Hostler JM,Mitchell JD, et al. Validation of the international medicalprevention registry on venous thromboembolism bleedingrisk score. Chest 2016; 149 (2):372-9. DOI: 10.1378/chest.14-2842.

  25. Gharaibeh L, Sartawi H, Ayyad D, Juma T, Albassoumi K, IsmailE. Evaluation of venous thromboembolism prophylaxisin a major hospital in a developing country. Int J Clin Pharm2017; 39 (4): 881-887. DOI: 10.1007/s11096-017-0494-7.

  26. Kahn SR, Panju A, Geerts W, Pineo GF, Desjardins L, TurpieAG, Glezer S, Thabane L, Sebaldt RJ; CURVE study investigators.Multicenter evaluation of the use of venous thromboembolismprophylaxis in acutely ill medical patients inCanada. Thromb Res 2007; 119 (2): 145-55. DOI: 10.1016/j.thromres.2006.01.011.

  27. Atmakusuma TD, Tambunan KL, Sukrisman L, Effendi S,Rachman A, Setiawati A, Et al. Underutilization of anticoagulantfor venous thromboembolism prophylaxis in threehospitals in Jakarta. Acta Med Indones 2015; 47 (2): 136-45.

  28. Dennis R, Roa J, Villadiego J, Méndez F, Vieda E, RestrepoH. Profilaxis de la tromboembolia venosa en pacientescolombianos de tratamiento médico o quirúrgico: resultadospara Colombia del estudio ENDORSE. Biomedica2011; 31: 200-8.

  29. Sáenz O, Vergara V, González F, Bonilla P, Russi J, Rojas A, Etal. Estudio PETRO: evaluación de tromboprofilaxis y riesgoembólico en pacientes hospitalizados en una instituciónde tercer nivel en Bogotá, Colombia. Rev Colomb Neumol2017; 29 (1): 7-18.

  30. Gazitúa R, Saavedra S, Conte G, Figueroa M. Tromboprofilaxisen pacientes médicos hospitalizados. ¿A todos porigual?. Rev Hosp Clin Univ Chile 2015; 26: 185-97.

  31. Nieto JA, Cámara T, Camacho I; MEDITROM Investigators.Venous thromboembolism prophylaxis in acutely ill hospitalizedmedical patients. A retrospective multicenter study.Eur J Intern Med 2014; 25 (8): 717-23. DOI: 10.1016/j.ejim.2014.07.005.

  32. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM,Lassen MR, et al. Prevention of venous thromboembolism:American College of Chest Physicians Evidence-Based ClinicalPractice Guidelines (8th edition). Chest 2008; 133 (6Suppl): 381S-453S. doi: 10.1378/chest.08-0656.

  33. Espinoza A. Tromboprofilaxis en el paciente quirúrgico. RevChil Anestesia 2008; 37: 9-20.

  34. Viruez JL, Vera O, Torrez K. Enfermedad tromboembólicavenosa: ¿Una patología frecuente poco reconocida? RevMed La Paz 2011; 17 (2): 13-20.

  35. De Ándres F, Ventura V, Silveira G, Carlomagno A, BaccelliA, López I, Et al. Estudio de una cohorte de pacientes conenfermedad tromboembólica venosa en seguimiento ambulatorio.Rev Urug Med Interna 2017; 2: 29-32.

  36. Lixon A, Rahman EU, Mohan CA, Bhattarai B, Schmidt F.An unusual case of bilateral pulmonary embolism in apatient on dual venous thromboprophylaxis, secondaryto heparin induced thrombocytopenia. J CommunityHosp Intern Med Perspect. 2018; 8 (6): 376-379. DOI:10.1080/20009666.2018.1554099.

  37. Muñoz M, Serrano M, Díaz L, Cigüenza R, Antolín J. Enfermedadtromboembólica venosa: análisis de 239 casos. AnMed Interna 2006; 23 (12):565-568.

  38. Mateo J. Nuevos anticoagulantes orales y su papel en lapráctica clínica. Rev Esp Cardiol Supl 2013; 13 (C): 33-41.DOI: 10.1016/S1131-3587(13)70057-8.

  39. Berkovits A, Mezzano D. Nuevos anticoagulantes orales:actualización. Rev Chil Cardiol 2017; 36: 254-263. DOI:10.4067/S0718-85602017000300254.

  40. Jaramillo R, Jiménez J. Uso de los anticoagulantes oralesdirectos en la práctica clínica. Rev Fac Med 2016; 64 (2):295-308.

  41. Dennis R, Acevedo J, Restrepo H, Hernández J, Rivas E,Sabogal J. ¿Es apropiada la profilaxis actual del tromboemblismovenoso en pacientes médicos? Acta Med Colomb2009; 34 (1): 11-16.

  42. Diaztagle J, Cely J, Sánchez J, Sánchez F, Mendoza E. Tromboprofilaxisen el paciente médico hospitalizado por medicinainterna. Acta Médica Colombiana 2015; 40 (3): 227-233.

  43. Rivast R. Complicaciones mecánicas de los accesos venososcentrales. Rev Med Clin Condes 2011; 22 (3): 350-360.

  44. Fuente R, Gutiérrez D, Pedrosa M, Flota C, Vaquero C.Trombosis focal de vena femoral común: manifestacióninicial de linfoma no Hodgkin difuso de células grandes B.Rev Colomb Cancerol 2018; 22 (1): 53-56. DOI: 10.1016j.rccan.2017.05.003.

  45. Schünemann HJ, Ventresca M, Crowther M, Briel M, ZhouQ, Garcia D, Et al; IPDMA heparin use in cancer patientsresearch group. Use of heparins in patients with cancer:individual participant data meta-analysis of randomisedtrials study protocol. BMJ Open 2016; 6 (4): e010569. DOI:10.1136/bmjopen-2015-010569.

  46. Caruso V, Di Castelnuovo A, Meschengieser S, Lazzari MA,de Gaetano G, Storti S, Et al. Thrombotic complicationsin adult patients with lymphoma: a meta-analysis of 29independent cohorts including 18 018 patients and 1149events. Blood 2010; 115 (26): 5322-8. DOI: 10.1182/blood-2010-01-258624.

  47. Korte W. Cancer and thrombosis: an increasingly importantassociation. Support Care Cancer 2008; 16 (3): 223-8. doi:10.1007/s00520-007-0376-y.

  48. Chamoun N, Ramia E, Lteif C, Salameh P, Zantout H,Ghanem G, Et al. Assessment of bleeding in chronicliver disease and coagulopathy using the IMPROVEbleeding criteria. Curr Med Res Opin 2018: 1-7. DOI:10.1080/03007995.2018.1525343.

  49. Rosenberg D, Eichorn A, Alarcon M, McCullagh L, McGinn T,Spyropoulos AC. External validation of the risk assessmentmodel of the International Medical Prevention Registry onVenous Thromboembolism (IMPROVE) for medical patientsin a tertiary health system. J Am Heart Assoc 2014; 3 (6):e001152. DOI: 10.1161/JAHA.114.001152.




2020     |     www.medigraphic.com